Segall Bryant & Hamill LLC Invests $713,000 in Emergent Biosolutions Inc. $EBS

Segall Bryant & Hamill LLC bought a new position in shares of Emergent Biosolutions Inc. (NYSE:EBS) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 80,849 shares of the biopharmaceutical company’s stock, valued at approximately $713,000. Segall Bryant & Hamill LLC owned 0.15% of Emergent Biosolutions at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Millennium Management LLC grew its holdings in Emergent Biosolutions by 68.9% during the 1st quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock worth $12,162,000 after acquiring an additional 1,020,582 shares during the last quarter. American Century Companies Inc. increased its position in shares of Emergent Biosolutions by 3.9% in the 3rd quarter. American Century Companies Inc. now owns 2,382,378 shares of the biopharmaceutical company’s stock valued at $21,013,000 after buying an additional 90,216 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Emergent Biosolutions by 108.9% in the 2nd quarter. Geode Capital Management LLC now owns 1,278,998 shares of the biopharmaceutical company’s stock valued at $8,162,000 after purchasing an additional 666,708 shares during the period. Goldman Sachs Group Inc. boosted its stake in Emergent Biosolutions by 12.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,090,655 shares of the biopharmaceutical company’s stock worth $5,301,000 after purchasing an additional 121,583 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in Emergent Biosolutions by 5.9% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 986,673 shares of the biopharmaceutical company’s stock valued at $6,295,000 after acquiring an additional 55,046 shares in the last quarter. 78.40% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Emergent Biosolutions in a research note on Tuesday, December 16th. Wall Street Zen cut Emergent Biosolutions from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Finally, Weiss Ratings lowered Emergent Biosolutions from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Emergent Biosolutions has a consensus rating of “Hold” and a consensus target price of $15.00.

Emergent Biosolutions Stock Down 1.8%

Shares of Emergent Biosolutions stock opened at $8.29 on Friday. The company has a debt-to-equity ratio of 1.09, a current ratio of 5.01 and a quick ratio of 2.41. The stock’s 50-day moving average is $11.29 and its 200 day moving average is $10.39. The firm has a market cap of $435.39 million, a price-to-earnings ratio of 9.87 and a beta of 2.41. Emergent Biosolutions Inc. has a one year low of $4.02 and a one year high of $14.06.

Emergent Biosolutions (NYSE:EBS) last issued its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.54). Emergent Biosolutions had a net margin of 7.08% and a return on equity of 15.86%. The firm had revenue of $148.70 million during the quarter, compared to the consensus estimate of $217.50 million. Equities research analysts anticipate that Emergent Biosolutions Inc. will post -0.63 EPS for the current year.

Emergent Biosolutions Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.